Answers are grounded in this paper and cite their sources.
Introduction: Coronavirus disease 2019 (COVID-19) pneumonia is heterogeneous disease with variable effect on lung parenchyma, airways, and vasculature, leading to long-term effects on lung functions. Materials and Methods: Multicentric, prospective, observational, and interventional study included 1000 COVID-19 cases confirmed with reverse transcription-polymerase chain reaction. All cases were assessed with lung involvement documented and categorized on high-resolution computed tomography (CT) of the thorax, oxygen saturation, inflammatory marker as interleukin-6 (IL-6) at entry point and follow-up. Age, gender, comorbidity, and use bilevel positive airway pressure/noninvasive ventilation (BIPAP/NIV) and outcome as with or without lung fibrosis as per CT severity were key observations. Statistical analysis is performed using Chi-square test. Results: Age (<50 and > 50 years) and gender (male versus female) has significant association with IL-6 ( P < 0.00001) and ( P < 0.010], respectively. CT severity score at entry point has significant correlation with IL-6 level ( P < 0.00001) IL-6 level has significant association with duration of illness ( P < 0.00001). Comorbidity as diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ischemic heart disease, and obesity has significant IL-6 level ( P < 0.00001). IL-6 level has significant association with oxygen saturation ( P < 0.00001). BIPAP/NIV requirement during course hospitalization has significant association with IL-6 level ( P < 0.00001). Timing of BIPAP/NIV requirement during hospitalization has significant association with IL-6 level ( P < 0.00001) Serial IL-6 titer during hospitalization as compared to entry point normal and abnormal IL-6 has significant association in post-COVID lung fibrosis ( P < 0.00001). Conclusions: IL-6 is easily available, and universally acceptable inflammatory marker, documented crucial role in COVID-19 pneumonia in predicting the severity of illness, progression of illness including “cytokine storm” and assessing response to treatment during hospitalization.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: